Working to make the promise of precision medicine a reality
Matthew A. Call
Chief Operating Officer
Matthew Call joined Endocyte in 2003 and was recently named Chief Operating Officer, assuming operational responsibility for the firm. Prior to his role as COO, he led all strategic partnering and licensing transactions resulting in numerous successful processes, including Endocyte’s transformational inlicense of PSMA-617, which led to the $2.1B acquisition of Endocyte by Novartis, and the outlicensing process of Endocyte’s billion-dollar partnership with Merck for vintafolide, including a $120M upfront payment. While leading business development, Mr. Call also had responsibility for project management, strategic planning, competitive intelligence, product development and marketing functions. Prior to joining Endocyte, Mr. Call spent several years working in business development in the tech space, where he structured and managed strategic relationships with firms such as Hewlett-Packard, General Electric, and Disney. He received a BA from Brigham Young University and an MBA from Purdue University.
Vice President, Clinical Operations
Caryn Barnett joined Endocyte in January 2018 and was promoted to vice president of clinical operations in November 2018. Ms. Barnett has over 23 years of drug development experience. Prior to joining Endocyte, she worked at Eli Lily and Company in numerous roles in research and development, primarily in clinical. Ms. Barnett has worked across pre-clinical to post approval settings with experience in operations, project management and quality. She received a BSN in nursing from West Virginia University and an MSN in nursing from Indiana University.
Christopher Jordan, MSHS, RAC
Vice President, Regulatory Affairs
Christopher Jordan joined Endocyte in 2013 and was recently named Vice President of Regulatory Affairs. Prior to joining Endocyte, Mr. Jordan spent more than 25 years at Eli Lilly in a variety of drug development roles covering pre-clinical to post approval settings, including regulatory team leader for drug development and drug/device combination products. He received his BS in chemistry from Purdue University and a MSHS in regulatory affairs from George Washington University.
Christopher P. Leamon, PhD
Vice President, Research & Development
Dr. Christopher Leamon joined Endocyte in 1999 as our director of biology and biochemistry. He currently serves as our vice president of research and development. Prior to joining Endocyte, Dr. Leamon was employed in the pharmaceutical industry where he conducted discovery research in the field of peptide, oligonucleotide, liposome, and DNA drug delivery for GlaxoSmithKline, a healthcare company, and Ionis Pharmaceuticals, a biomedical pharmaceutical company. He holds a BS in chemistry from Baldwin Wallace University and a PhD in biochemistry from Purdue University.
David R. McAvoy, MSES, JD
General Counsel and Chief Compliance Officer
David McAvoy joined Endocyte in January 2018 and serves as General Counsel and Chief Compliance Officer. Before this, Mr. McAvoy was at Eli Lilly and Company, most recently as General Counsel of Lilly Emerging Markets, at the time, a $3 billion company division, and then in an executive management role running strategic alliances for the food animal production group at Lilly’s former Elanco Animal Health subsidiary. At Lilly, Mr. McAvoy was lead counsel for several iconic medicines, including Prozac® for depression, Gemzar® for pancreatic/lung cancers, and ReoPro®, one of the first interventional cardiology agents. He partnered with FDA to create important policy precedents in orphan drug, direct-to-customer advertising of pharmaceuticals, and clinical trial transparency. Mr. McAvoy earned a JD and MS in environmental science with highest honors from Indiana University and a BA in political science from the University of Notre Dame. He serves on the Board of Directors for The Villages of Indiana, Inc., championing families for abandoned and abused children.
Vice President, Quality
Becky Merlina joined Endocyte in December 2018 as Vice President of Quality. Prior to Endocyte, Ms. Merlina had a 26 year career at Eli Lily & Company where she was responsible for the audit program covering Clinical Development, Global Patient Safety, Regulatory Affairs, and US Customer Information, as well as GxP audits of operations in Lily’s affiliates. Ms. Merlina led a global team of managers and auditors who implemented the audit program and supported the business in preparing for and hosting regulatory inspections. She spent six years as a Director in the Medicines Quality Organization providing quality guidance to her business partners, and supporting product teams in Lily’s BioMedicines, Diabetes and Oncology business units throughout late-phase clinical development and numerous successful inspections. She held quality leadership roles in support of product research and development’s quality system, clinical trial materials manufacturing/packaging, and analytical sciences research and development. Ms. Merlina holds a BS in Pharmacy from Butler University.
Rich Messmann, MD, MHS, MSc
Vice President, Medical Affairs
Dr. Messmann joined Endocyte as senior director of medical affairs in early 2018 and now serves as vice president of medical affairs. Dr. Messmann is a medical oncologist with over 20 years of experience in conducting phase I-III clinical studies within government, academia and industry. After completing a medical oncology fellowship at the National Cancer Institute and obtaining an MHS in health science from Duke University, he served as deputy associate director of the NCI’s developmental therapeutics program (DTP) and as an attending physician for NCI clinical trials, specializing in the transition of experimental therapeutics from the late-preclinical stage into first-in-human phase I and phase II studies. Dr. Messmann has held leadership positions at Eli Lilly, Great Lakes Cancer Institute, ProNAi Therapeutics and Apexian Pharmaceuticals.
Beth A. Taylor, CPA
Vice President, Finance
Beth Taylor joined Endocyte as corporate controller in January 2011 and now serves as vice president of finance and chief accounting officer. She is responsible for financial planning, reporting, and control compliance. Ms. Taylor started her career with Deloitte and then served in various financial roles with Rolls-Royce and vice president and controller for Republic Airways. She has also served as corporate controller for companies owned by private equity firms to assist with building strong financial and control processes. She holds a BS in accounting from Kelly School of Business from Indiana University and holds a CPA license from the state of Indiana. She is a member of Financial Executives International (FEI) and holds a board position for the Indianapolis Chapter.
Iontcho Vlahov, PhD
Vice President, Discovery Chemistry
Dr. Iontcho Vlahov joined Endocyte in 1999 and serves as the vice president of discovery chemistry. . Before joining Endocyte, he was the head of discovery chemistry at Ivax Corp in Miami, Florida. Prior to that, he held various positions, including visiting scientist at Hercules, Inc.; senior research scientist at the University of Konstanz, Germany; research scientist at the Institute of Organic Chemistry, Bulgarian Academy of Sciences; and research associate at the University of Iowa. Dr. Vlahov is an Alexander von Humboldt Fellow and has published more than 55 scientific articles and 15 patents. He received his PhD in synthetic organic and structural chemistry from Ruhr University, Bochum, Germany.